{
    "organizations": [],
    "uuid": "ad3f568692c48ca10a7217386084cc8ea5479045",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-voyager-therapeutics-announces-fda/brief-voyager-therapeutics-announces-fda-clearance-of-investigational-nda-for-vy-aadc-idUSASB0C1UT",
    "ord_in_thread": 0,
    "title": "BRIEF-Voyager Therapeutics Announces FDA Clearance Of Investigational NDA For VY-AADC",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 23 (Reuters) - Voyager Therapeutics Inc:\n* VOYAGER THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR VY-AADC FOR ADVANCED PARKINSON’S DISEASE\n* VOYAGER THERAPEUTICS INC - CONTINUE TO PLAN TO DOSE FIRST PATIENT IN PIVOTAL PHASE 2-3 PROGRAM FOR ADVANCED PARKINSON‘S DISEASE DURING Q2 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-23T20:08:00.000+02:00",
    "crawled": "2018-01-24T15:36:47.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "voyager",
        "therapeutic",
        "inc",
        "voyager",
        "therapeutic",
        "announces",
        "fda",
        "clearance",
        "investigational",
        "new",
        "drug",
        "application",
        "advanced",
        "parkinson",
        "disease",
        "voyager",
        "therapeutic",
        "inc",
        "continue",
        "plan",
        "dose",
        "first",
        "patient",
        "pivotal",
        "phase",
        "program",
        "advanced",
        "parkinson",
        "disease",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}